Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities

Lukasz Komorowski(Medical University of Warsaw), Małgorzata Firczuk(Medical University of Warsaw), Elżbieta Patkowska(Institute for Transfusion Medicine), Klaudyna Fidyt(Polish Academy of Sciences)

International Journal of Molecular Sciences

August 12, 2020

10.3390/ijms21165776

Cited by 36

Related Papers

<i>β</i>‐caryophyllene and <i>β</i>‐caryophyllene oxide—natural compounds of anticancer and analgesic properties

|Cancer Medicine|2016|642

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|390

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy

|Blood|2022|129

Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma

|Oncotarget|2015|47

Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate

|Redox Biology|2018|42